MeSH D016411 - t-cell lymphoma peripheral
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Acrotech Biopharma | Belinostat | Beleodaq | 2026-08-10 | 2014-07-03 | ||
| Pralatrexate | Folotyn | 2022-07-16 | 2009-09-24 | |||
| Bristol Myers Squibb | Romidepsin | Istodax | 2009-11-05 | |||
| Fresenius Kabi | Romidepsin | Romidepsin | 2021-10-12 | |||
| Teva | Romidepsin | Romidepsin | 2020-03-13 |
Clinical Trials
Historical Success Rate
Phase 1
72%67/93
Phase 2
24%22/93
Phase 3
29%7/24
Approved: 3Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use